As the 2025 American Association for Cancer Research (AACR) annual meeting wraps up, we’re reflecting on the groundbreaking science, new collaborations, and the unveiling of what’s next in cancer research. This year, we were proud to showcase how AVITI24™, the world’s first intelligent multiomics platform, is transforming the pace and precision of cancer research and announce accelerated timelines for new direct in sample sequencing (DISS) capabilities.
Throughout the conference, the energy at our booth was electric as researchers, collaborators, and partners gathered to see how AVITI24 is setting a new standard in multiomics with faster insights and smarter science.
A major milestone: accelerated rollout of direct in sample sequencing
For us, one of the most exciting moments of the event was our announcement of the accelerated rollout of DISS, a transformative technology that enables spatially-resolved, single cell molecular insights directly in their biological context—all completely library-prep free. It unlocks research possibilities across new applications, from lineage tracing to CRISPR pooled screens and more. We can’t wait to see how cancer researchers will use it to advance their discovery.
Along with this announcement, we held daily presentations sharing all things AVITI24 and DISS in our meeting room. The talk, "Leveraging High Dimensional Multiomic Screens with AVITI24 to Accelerate Drug Discovery", highlighted ways researchers can now perform integrated multiomic analyses at scale, drastically shortening discovery timelines and expanding insights across biological systems. We took a deep dive into the DISS technology and shared real world data using the technology for optical pooled screens.
Innovation in action at our scientific posters
While new capabilities on the AVITI24 were a major focus at the show, our scientific team also shared their work to develop novel applications of our Trinity™ hybrid capture sequencing workflow for cancer research. If you missed our posters or want to take a closer look, we’ve made all the posters available for download.
Optical pooled screens with massively multiplexed phenotypic readouts on AVITI24
Optical pooled screening (OPS) is a powerful tool for linking morphological cellular phenotypes with in situ readouts of genetic perturbations. However, adoption of OPS has been restricted to a small number of labs due to the manual workflows and expertise required for data generation and computational analysis.
Here, we establish a fully automated end-to-end workflow for OPS on the AVITI24 system. We demonstrate highly accurate in sample sequencing of genetic perturbations combined with a highly multiplexed AVITI24 phenotyping panel to perform a 500-gene CRISPR screen for regulators of complex cellular processes. This work lays the foundation for automated OPS data generation, supporting rich profiling of perturbation effects at unprecedented scale.
Streamlined DNA/RNA sequencing from biopsies
Combined analyses of RNA transcript variations and comprehensive genomic sequencing allows for cross-validation of somatic mutations, improvement of sensitivity, and understanding of mutation effects on gene expression.
Here, we employed the novel Trinity target capture technology to simultaneously capture both RNA and DNA libraries in a single hybridization reaction. This optimized workflow significantly decreases sample-to-answer time and showed ~ 10% higher mean target coverage compared to data generated using conventional target capture workflow.
Mechanism of action discovery for cancer therapies with AVITI24
For decades, cancer therapy research relied on isolated analyses of transcriptomics, proteomics, or cell morphology to resolve heterogeneous responses. Integrating these readouts through multiplexed analysis enables a comprehensive understanding of how gene expression relates to functional outcomes and phenotypic effects, offering a holistic view for research of cellular processes impacted by treatment.
Here, we utilized AVITI24 to resolve complex systemic responses to tyrosine kinase inhibitors. By consolidating multiomic data in a single assay, this platform resolves multidimensional mechanisms underlying tumor responsiveness and drug resistance. By bridging molecular and morphology insights, our study provides a powerful framework for studying the intricate dynamics of targeted therapies, paving the way for innovative strategies to enhance cancer treatment and personalize patient care.
Rapid detection of myeloid malignancy mutations
Hybrid capture technology is a powerful and cost-effective tool to detect somatic mutations in precision oncology research. Traditional hybrid capture workflows involve several time-consuming steps prior to sequencing which can delay results.
Here, we combine Trinity hybrid capture and rapid AVITI sequencing protocol to deliver targeted sequencing results within 12 hours. We applied this specialized Trinity workflow with a custom myeloid panel based on a design used by Genomics Medicine Sweden to detect mutations in reference DNA and patient blood, bone marrow, and fresh frozen tissue. This rapid, accurate, and robust solution for targeted sequencing offers significant advancements in turnaround time for hematology malignancy research.
Thank you
To everyone who visited us at AACR 2025 — thank you. Whether you stopped by our booth, joined a session, or downloaded a poster, your passion for advancing cancer research fuels everything we do.
Let’s keep building momentum. Contact us to explore how AVITI24 can support your next breakthrough.